| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Throughout the last three months, 7 analysts have evaluated Praxis Precision Medicine (NASDAQ:PRAX), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 6 | 1 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 1 | 0 | 0 | 0 |
| 3M Ago | 2 | 0 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $123.57, a high estimate of $155.00, and a low estimate of $105.00. This current average reflects an increase of 12.34% from the previous average price target of $110.00.
The standing of Praxis Precision Medicine among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Yatin Suneja | Guggenheim | Announces | Buy | $155.00 | - |
| Joon Lee | Truist Securities | Maintains | Buy | $150.00 | $150.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $105.00 | $105.00 |
| Joel Beatty | Baird | Announces | Outperform | $117.00 | - |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $105.00 | - |
| Kambiz Yazdi | Jefferies | Raises | Buy | $128.00 | $75.00 |
| Douglas Tsao | HC Wainwright & Co. | Maintains | Buy | $105.00 | - |
Capture valuable insights into Praxis Precision Medicine's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Praxis Precision Medicine analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Challenges: Praxis Precision Medicine's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately -36.9%. This indicates a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Praxis Precision Medicine's net margin excels beyond industry benchmarks, reaching -9177.03%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Praxis Precision Medicine's ROE stands out, surpassing industry averages. With an impressive ROE of -26.43%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Praxis Precision Medicine's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -23.38%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.01, Praxis Precision Medicine adopts a prudent financial strategy, indicating a balanced approach to debt management.
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: PRAX
